The use of a complex of natural antimicrobial peptides and cytokines for treatment of male infertility and chronic prostatitis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Chronic prostatitis (CP) has long been considered one of the common causes of male infertility. The influence of therapy for CP on spermatogenesis is well studied. However, recently, especially in the era of the new coronavirus infection (COVID-19), much attention has been paid to the effects of cytokines on the pathogenesis of the inflammatory process, and their impact on male fertility. Aim. To study the effect of a complex of natural antimicrobial peptides and cytokines (Superlymph) on ejaculate, MAR test, oxidative stress (OS), and sperm DNA fragmentation (SDF) in men with infertility and a history of CP. In some patients, the level of cytokines before and after treatment was determined. Materials and methods. A total of 583 infertile men with a history of CP, aged 18-75 years, were screened according to the inclusion/ exclusion criteria. In group I, patients received antioxidant stimulation of spermatogenesis (triovit, trental, mexidol) in combination with a complex of natural antimicrobial peptides and cytokines (Superlymph) one suppository 25 IU at night for 20 days for 1-3 weeks and for 6-8 weeks for 2 months. In group II, antioxidant stimulation of spermatogenesis was prescribed along with suppositories for the prevention of CP for 2 months. The evaluated criteria included sperm analysis, MAR test, oxidative stress in spermatozoa (reactive oxygen species (ROS)) and SDF. The levels of seminal plasma cytokines were also measured before and after treatment in 32 patients using the Bio-Plex Pro panel for the simultaneous determination of 17 human cytokines, the Human Cytokine 17-plex Assay. Statistica-10 software was used for statistical analysis (p<0.05). Results. Of 135 eligible patients, results were collected from 125 men (mean age 31.7 ± 13.4 years). In group I, there was a more pronounced increase in motility by 42.3%, a decrease in the MAR-test level by 64.7%, oxidative stress in spermatozoa by 56.1%, and SDF by 25.6%, compared to group II (30.4 %, 10.5%, 45.7%, 21.9%), respectively. All these changes were significant with the exception of a decrease in the level of SDF. In group I, there was a predominant increase in the activity of anti-inflammatory cytokines (IL-4, 10, 13), a decrease in the level of pro-inflammatory cytokines ((IL-2, 12). In group II, there was a significant decrease in both pro-inflammatory (IL-2, 6, 8), and anti-inflammatory cytokines (IL-4). The remaining changes were insignificant. Among mild side effects, there were a change in the color of the sclera in 4 (3.2%), anal pain in 3 (2.4%), a decrease in libido in 2 (1.6%) patients. No differences between groups in the frequency of side effects were recorded (p>0.05). Conclusion. Antioxidant stimulation of spermatogenesis in infertile men and CP is an effective and safe. The addition of a complex of natural antimicrobial peptides and cytokines (Superlymph) leads to a more profound increase in sperm motility, a decrease in the MAR-test, oxidative stress in sperm cells, which potentiates the effects of therapy. The use of Superlymph is accompanied by a more pronounced positive effect on pathospermia, an increase in anti-inflammatory and a decrease in pro-inflammatory cytokines. In the contrary, in control group, where patients received antioxidant stimulation of spermatogenesis, only a decrease in the level of main cytokines was observed. The effect of a complex of natural antimicrobial peptides and cytokines (Superlymph) on the level of SDF, as well as the relationship with fertility and childbirth rates, requires further study.

Full Text

Restricted Access

About the authors

R. I Ovchinnikov

National Medical Research Center of Obstetrics, Gynecology and Perinatology named after V.I. Kulakov of the Ministry of Health of Russia; Russian-Finnish center of reproductive medicine “Scanfert”

Email: riododc@rambler.ru
Ph.D., Head of the Department of the Development of Andrology, Head of the Department of Andrology and Urology; Head of the Department of Andrology and Urology in the clinic

A. Yu. Popova

National Medical Research Center of Obstetrics, Gynecology and Perinatology named after V.I. Kulakov of the Ministry of Health of Russia

Email: a_popova@oparina4.ru
Ph.D., senior researcher at the Department of Andrology and Urology

V. V Vtorushina

National Medical Research Center of Obstetrics, Gynecology and Perinatology named after V.I. Kulakov of the Ministry of Health of Russia

Email: v_vtorushina@oparina4.ru
Ph.D., physician at the clinical laboratory diagnostics of clinical immunology

A. A Muradyan

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)

Ph.D. student at the Department of Obstetrics, Gynecology, Perinatology and Reproductology

S. I Gamidov

National Medical Research Center of Obstetrics, Gynecology and Perinatology named after V.I. Kulakov of the Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)

Email: s_gamidov@oparina4.ru
Ph.D., MD, professor at the Department of Obstetrics, Gynecology, Perinatology and Reproductology; Chief of the Department of Andrology and Urology

References

  1. Попова А.Ю., Гамидов С.И., Овчинников Р.И. Использование антиоксидантов в комбинированной терапии мужского бесплодия при воспалительных заболеваниях. Эффективная фармакотерапия. Урология и Нефрология. 2015;4(35):34-38
  2. Olayemi F.O. A review on some causes of male infertility. Afr J Biotechnol. 2010;9:2834-3842.
  3. Sinclair S. Male infertility: nutritional and environmental considerations. Altern Med Rev. 2000;5:28-383.
  4. Syriou V., Papanikolaou D., Kozyraki A., Goulis D.G. Cytokines and male infertility. Eur Cytokine Netw. 2018;29(3):73-82. Doi: 10.1684/ ecn.2018.0412.
  5. Dutta S., Sengupta P, Slama P. et al. Oxidative Stress, Testicular Inflammatory Pathways, and Male Reproduction. J Mol Sci 2021 ;22(18): 10043. doi: 10.3390/ijms221810043.
  6. La Vignera S, Condorelli R.A, Vicari E, Tumino D, Morgia G, Favilla V, Cimino S & Calogero A.E. Markers of semen inflammation: supplementary semen analysis? J Reprod Immunol. 2013:100: 2-10. Doi:10.1016/j. jri.2013.05.001.
  7. Dinarello C.A. Historical insights into cytokines. Eur J Immunol 2007; 37(1):34-45.
  8. Zhang J-M., An J. Cytokines, inflammation and pain.Int Anesthesiol Clin 2007;45(2):27-37.
  9. Hedger M.P. Testicular leukocytes: what are they doing? Rev Reprod 1997; 2: 38-47.
  10. Maegawa M., Kamada M., Irahara M., et al. A repertoire of cytokines in human seminal plasma. J Reprod Immunol. 2002; 54(1-2):33-42.
  11. Cheng C. Y., Mruk D.D. The blood-testis barrier and its implications for male contraception. Pharmacol Rev 2012; 64(1):16-64.
  12. Kate L., Loveland., Britta Klein, Dana Pueschl et al. Cytokines in Male Fertility and Reproductive Pathologies: Immunoregulation and Beyond. Front Endocrinol (Lausanne). 2017 Nov 20;8:307. Doi: 10.3389/ fendo.2017.00307. eCollection 2017.
  13. Kohchi C., Inagawa H., Nishizawa T., Soma GI. ROS and innate immunity. Anticancer Res 2009;29(3):817-22.
  14. Goldman R., Ferber E., Zort U. Reactive oxygen species are involved in the activation of cellular phospholipase A2. FEBS Lett 1992;309(2):190-192.
  15. Fraczek M., Kurpisz M. Inflammatory mediators exert toxic effects of oxidative stress on human spermatozoa. J Androl 2006;28(2):325-333.
  16. Depuydt E., Comhaire H. The relation between reactive oxygen species and cytokines in andrological patients with or without male accessory gland infection. J Androl 1996;17(6):699-707.
  17. Hedger M.P. Toll-like receptors and signalling in spermatogenesis and testicular responses to inflammation - a perspective. J Reprod Immunol 2011;88(2):130-41.
  18. Dousset B., Hussenet F., Daudin M., Bujan L., Foliguet B., Nabet P. Seminal cytokine concentrations (IL-1 , IL-2, IL-6, sR IL-2, sR IL-6), semen parameters and blood hormonal status in male infertility. Hum Reprod 1997;12(7):1476-1479.
  19. Heidargholizadeh S., Aydos S.E., Yukselten Y., Ozkavukcu S., Sunguroglu A, Aydos K. A differential cytokine expression profile before and after rFSH treatment in Sertoli cell cultures of men with nonob- structive azoospermia. Andrologia. 2017;49(4):e12647.
  20. Lotti F., Corona G., Mondaini N., et al. Seminal, clinical and colour-Doppler ultrasound correlations of prostatitis-like symptoms in males of infertile couples. Andrology 2014;2(1):30-41
  21. An L.F., Zhang X.H., Sun X.T., Zhao L.H., Li S., Wang W.H. Unexplained infertility patients have increased serum IL-2, IL-4, IL-6, IL-8, IL-21, TNF, IFN and increased Tfh/CD4T cell ratio: Increased Tfh and IL-21 strongly correlate with presence of autoantibodies. Immunol Invest. 2015;44(2):164-173.
  22. Alsaimary IEA. Evaluation of serum levels of pro-inflammatory cytokines (interleukins 2, 6, 8) in fertile and infertile men. Donnish J Microbiol Biotechnol Res 2014;1(2):23-34.
  23. Hagan S., Khurana N., Chandra S. et al. Differential expression of novel biomarkers (TLR-2, TLR-4, COX-2, and Nrf-2) of inflammation and oxidative stress in semen of leukocytospermia patients. Аndrology. 2015;3(5):848-55. doi: 10.1111/andr.12074
  24. Agarwal A., Prabakaran S.A. Said T.M. Prevention of oxidative stress injury to sperm. J Androl. 2005;26:654-660.
  25. Dziadecki W., Celinska A., Fracki S., Bablok L., Barcz E.Interleukin 6 and interleukin 8 concentrations in seminal plasma of male with seminogram abnormalities. Centr Eur J Immunol 2010;35:162-167.
  26. Бухарин О.В., Кузьмин М.Д., Перунова Н.Б. и др. Характеристика микробиоты и цитокинового профиля плазмы сперматозоидов у мужчин с хроническим бактериальным простатитом. Урология. 2020;(5):67- 72
  27. Бухарин О.В., Кузьмин М.Д., Перунова Н.Б. и соавт. Диагностический цитокиновый маркер мужского бесплодия - интерлейкин 4. Клин Лабораторная диагностика. 2022;67(3):151-157. doi: 10.51620/08692084-2022-67-3-151-157
  28. Daniela Andrea Paira, Silene Silvera-Ruiz, Andrea Tissera et al.Interferon-"/, IL-17, and IL-1p impair sperm motility and viability and induce sperm apoptosis. Cytokine. 2022;152:155834. doi: 10.1016/j.cyto.2022.155834. Epub 2022 Feb 22
  29. Farzaneh Fesahat, Efat Norouzi, Seyed Mohammad Seifati et al. Impact of Vitamin C on Gene Expression Profile of Inflammatory and Anti-Inflammatory Cytokines in the Male Partners of Couples with Recurrent Pregnancy Loss.Int J Inflam. 2022;2022:1222533. doi: 10.1155/2022/1222533
  30. Сухих Г.Т., Попова А.Ю., Овчинников Р.И., Ушакова И.В. Влияние комплекса Сперотон на функциональные характеристики сперматозоидов у мужчин с идиопатической патозооспермией. Проблемы репродукции. 2016;4:106-109
  31. Smits R.M., Mackenzie-Proctor R., Yazdani A., et al. Antioxidants for male subfertility. Cochrane Database Syst Rev. 2019;3(3):CD007411. doi: 10.1002/14651858.CD007411.pub4
  32. Овчинников Р.И., Попова А.Ю., Гамидов С. И. Антиоксидантная терапия - ключ к лечению идиопатического мужского бесплодия. 2017;20:177-181. doi: 10.21518/2079-701X-2017-20-177-181
  33. Гамидов С.И., Овчинников Р.И., Попова А.Ю. Двойное слепое рандомизированное плацебо-контролируемое исследование эффективности и безопасности комплекса ацетил+-карнитина, L-карнитина фумарата и альфа-липоевой кислоты (СпермАктин® Форте) в лечении мужского бесплодия. Урология. 2019;4:62-68. doi: 10.18565/urology.2019.4.61-68.
  34. Burton G.W., Traber M.G. Vitamin E: Antioxidant activity, biokinetics, and bioavailability. Annu Rev Nutr 1990;10:357-382.
  35. Keskes-Ammar L., Feki-Chakroun N., Rebai T., Sahnoun Z., Ghozzi H., Hammami S., et al. Sperm oxidative stress and the effect of an oral Vitamin E and selenium supplement on semen quality in infertile men. Arch Androl 2003;49:83-94.
  36. Ahsan U., Kamran Z., Raza I., Ahmad S., Babar W., Riaz M.H., et al. Role of selenium in male reproduction - A review. Anim Reprod Sci 2014;146:55- 62.
  37. Lenzi A., Lombardo F., Sgro P., Salacone P., Caponecchia L., Dondero F., Gandini L. Use of carnitine therapy in selected cases of male factor infertility: A double-blind crossover trial. Fertil. Steril. 2003;79:292-300.
  38. Instructions for the use of the drug Mexidol.Russian (Инструкция по применению препарата Мексидол). https://www.rlsnet.ru/tn_index_id_679.htm
  39. Гамидов С.И., Овчинников Р.И., Попова А.Ю. и др. Адъювантная антиоксидантная терапия у больных бесплодием при варикоцеле. Урология. 2017;2(Прил. 2):64-72. Doi: https://dx.doi.org/10.18565/urol.2017.2-supplement.64-72.
  40. Harris M., Taylor G. Medical statistics made easy. London: Taylor and Francis; 2006.
  41. Korneev I.A. Male infertility under oxidative stress: ways to solve the problem. Urologiia. 2022;1:102-108.Russian (Корнеев И.А. Мужское бесплодие при оксидативном стрессе: пути решения проблемы. Урология 2022; 1:102-108). Doi: https://dx.doi.org/10.18565/urology.2022.1.102-108
  42. Agarwal A., Parekh N., Panner Selvam M.K., Henkel R., Shah R., et al. Male Oxidative Stress Infertility (MOSI): Proposed Terminology and Clinical Practice Guidelines for Management of Idiopathic Male Infertility. World J Mens Health. 2019;37(3):296-312. doi: 10.5534/wjmh.190055.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies